WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has been granted Fast Track Designation in the US for the development of FARXIGA ® (dapagliflozin) to reduce the risk of hospitalization for heart ...

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Farxiga has been approved to reduce the risk of hospitalization for heart failure in ...

Patients with a certain type of heart failure will soon have a new treatment available. The Food and Drug Administration has approved AstraZeneca’s Farxiga (dapagliflozin) oral tablets for adults with ...

AstraZeneca is on its way to scoring a key new nod for SGLT2 diabetes drug Farxiga, and the FDA just sped things up. The agency doled out its fast track designation to Farxiga in chronic kidney ...

Discovery may pave the way for a new class of medication. AstraZeneca's diabetes drug, Farxiga, has become the first in its class to receive FDA approval as a treatment for heart failure. "It's great ...

AstraZeneca’s Farxiga just won European approval in Type 1 diabetes, but its prospects in the U.S. are less certain. The FDA’s rejection of Sanofi and Lexicon Pharmaceuticals’ would-be rival Zynquista ...

(RTTNews) - The US Food and Drug Administration AstraZeneca's Farxiga (dapagliflozin) to improve glycemic control in pediatric patients with type-2 diabetes or T2D aged 10 years and older. The FDA ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- ...

Medication vials marked for calibration await counting at the Exchange Pharmacy at Joint Base Andrews, Md., July 27, 2023. (Photo by Staff Sgt. Jared Duhon/U.S. Air Force) A Maryland board tasked with ...

In patients tolerating FARXIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily To reduce the risk of hospitalization for heart failure in ...